Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease

Stroke

Volumn 40, Issue 1, 2009, Pages 147-155

  Mosca, Lori ^a,j   Grady, Deborah ^b   Barrett Connor, Elizabeth ^c   Collins, Peter ^d   Wenger, Nanette ^e   Abramson, Beth L ^f   Paganini Hill, Annlia ^g   Geiger, Mary Jane ^h   Dowsett, Sherie A ^h   Amewou Atisso, Messan ^h   Kornitzer, Marcel ⁱ  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h ELI LILLY AND COMPANY   (United States)

ⁱ FREE UNIVERSITY OF BRUSSELS   (Belgium)

^j NEW YORK PRESBYTERIAN HOSPITAL   (United States)

more..

Author keywords

Clinical trial; Stroke; Venous thromboembolism

Indexed keywords

PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORBIDITY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STROKE; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY DISEASE; INCIDENCE; MIDDLE AGED; MORTALITY; RISK ASSESSMENT; RISK FACTOR; SMOKING; TREATMENT OUTCOME;

COMORBIDITY; CORONARY ARTERY DISEASE; HUMANS; INCIDENCE; MIDDLE AGED; MORTALITY; POSTMENOPAUSE; RALOXIFENE; RISK ASSESSMENT; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SMOKING; STROKE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 60549114717     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.518621     Document Type: Article

References (22)

1. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady G, Kornitzer M, McNabb MA, Wenger NK. Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125-237.
2. Stefanick ML. Risk-benefit profiles of raloxifene for women. N Engl J Med. 2006;355:190-192.
3. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/ progestin Replacement Study. Ann Intern Med. 2000;132:689-696.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
5. Grady D, Ettinger B, Moscarelli E, Plouffe L Jr, Sarkar S, Ciaccia A, Cummings S; Multiple Outcomes of Raloxifene Evaluation Investigators. Safety and adverse effects associated with raloxifene: Multiple outcomes of raloxifene evaluation. Obstet Gynecol. 2004;104:837-844.
6. Mosca L, Barrett-Connor E, Wenger N, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright TJ, Helterbrand JD, Anderson PW. Design and methods of the Raloxifene Use For the Heart (RUTH) Study. Am J Cardiol. 2001;88:392-395.
7. A multinational case- control study of cardiovascular disease and steroid hormone contraceptives. Description and validation of methods. WHO Collaborative Study of Cardiovascular and Steroid Hormone Contraception. J Clin Epidemiol. 1995;48:1513-1547.
8. Hendrix SL, Wassertheil-Smoller, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner J; WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation. 2006;113:2425-2434.
9. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative. JAMA. 2003;289:2717-2719.
10. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-1249.
11. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell W. The effects of tibolone in older postmenopausal women. Results of the Long-Term Intervention on Fractures with Tibolone (LIFT) Randomized Trial. N Engl J Med. 2008;359:697-708.
12. Grobbee DE; LIFT Steering Committee. LIFT study to continue as planned. BMJ. 2005;333:843.
13. Bath PMW, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ. 2005;330:342.
14. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD; MORE Investigators. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four-year results from the MORE randomized trial. JAMA. 2002;287:847- 857.
15. Ensrud K, Genazzani AR, Geiger MJ, McNabb M, Dowsett SA, Cox DA, Barrett-Connor E. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol. 2006;97: 520-527.
16. Adachi JD, Chesnut CH, Brown JP, Christiansen C, Russo LA, Fernandes CE, Menegoci JC, Kung A, Chines AA, Bessac L, Chakrabarti D. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial [Abstract]. In: ASBMR 29th annual meeting program; September 16-19, 2007; Honolulu. Durham, NC: ASBMR Publications. Abstract W385, p 133.
17. Fisher B, Costantino JP, Wickerham DL, Redmon CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N, other National Surgical Adjuvant Breast and Bowel Project Investigators. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371-1388.
18. Dignam JJ, Fisher B. Occurrence of stroke with tamoxifen in NSABP B-24. Lancet. 2000;355:848-849.
19. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL III, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, for the National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. The NSABP study of tamoxifen and raloxifene (STAR) P-2 Trial. JAMA. 2006;295:2727-2741.
20. Azevedo GD, Franco RF, Baggio MS, Maranhão TM, Ferriani RA, Silva de Sá MF. Effects of raloxifene therapy on the anticoagulant system in postmenopausal women. Climacteric. 2003;6:140-145.
21. Sgarabotto M, Baldini M, Dei Cas A, Manotti C, Luciana Barilli A, Rinaldi M, Benassi L, Bacchi Modena A. Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a mul-ticenter, randomized, double-blind study. Thromb Res. 2007;119:85-91.
22. Cosman F, Baz-Hecht M, Cushman M, Vardy MD, Cruz JD, Nieves JW, Zion M, Lindsay R. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb Res. 2005;116:1-13